A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Non-Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2018
Price : $35 *
At a glance
- Drugs Plerixafor (Primary) ; Filgrastim
- Indications Non-Hodgkin's lymphoma; Stem cell mobilisation
- Focus Therapeutic Use
- Sponsors Genzyme Corporation; Sanofi
- 01 Nov 2018 Results assessing efficacy and safety of plerixafor, published in the International Journal of Hematology.
- 31 Aug 2018 Biomarkers information updated
- 29 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.